Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence
Myrelationshipwithalcohol.com Provides Information About the Disease, Personal Stories and an Interactive Questionnaire to Assess Drinking Patterns
DUBLIN, April 27, 2021 /PRNewswire/ Myrelationshipwithalcohol.com, a new website sponsored by Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), goes live today to offer education about alcohol dependence. Alcohol dependence is a treatable disease, but the belief that it is a moral or personal failing may prevent individuals from seeking help.
1 This new resource launches at a time when a growing number of people may be re-evaluating their drinking patterns.
Share this article
Share this article
DUBLIN, April 27, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy. The study will evaluate intravenously administered (IV) nemvaleukin in patients with mucosal melanoma and subcutaneously administered (SC) nemvaleukin in patients with advanced cutaneous melanoma. Nemvaleukin, Alkermes lead immuno-oncology candidate, is a novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. Nemvaleukin was granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA) in March 2021.
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -
News provided by
Share this article
Share this article
DUBLIN, April 20, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021.
The company s presentations included new exploratory analyses from the phase 3 ENLIGHTEN-2 study of olanzapine/samidorphan (LYBALVI™), formerly referred to as ALKS 3831, including:
Results from prespecified subgroup analyses evaluating olanzapine/samidorphan s effect on weight gain across several patient subgroups, including those known to be at higher risk for weight gain with olanzapine, based on sex, race, age and ba
(0)
DUBLIN, April 7, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. Kenilworth, NJ, USA) for a planned phase 3 study to evaluate nemvaleukin alfa ( nemvaleukin , formerly referred to as ALKS 4230), Alkermes novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD s KEYTRUDA
(pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021. We are pleased to collaborate with MSD to evaluate nemvaleukin in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer, a patient population for which there are limited treatment options available and overall survival remains low. Importantly,